Journal
ONCOTARGET
Volume 6, Issue 12, Pages 10045-10059Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3541
Keywords
vasorin; biomarker; hepatocarcinoma; subtractive-EMSA-SELEX; serum
Categories
Funding
- Major State Basic Research Development Program of China (973 Program) [2011CB811300, 2010CB912801]
- Chinese National High-Tech Research and Development Program [2012AA022501]
- National Natural Science Foundation of China [31370794, 81000930]
- Beijing Municipal Natural Science Foundation [7132142]
Ask authors/readers for more resources
We report a new biomarker of hepatocarcinoma, vasorin (VASN), screened by a subtractive EMSA-SELEX strategy from AFP negative serum of hepatocellular carcinoma (HCC) patients with extrahepatic metastases. VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97 cases of normal persons and 129 cases of hepatitis patients. Further validation by Q-PCR, IFA and Western blot showed higher expression of VASN at mRNA and protein levels in HCC cell lines and HCC tissues than in normal controls. RNA interference and forced overexpression assays verified that VASN promotes cell proliferation and migration and inhibits apoptosis. Down-regulation of microRNA miR145 and miR146a is an important mechanism leading to high expression of VASN. Conclusion: As a membrane protein and/or as free protein, VASN may be an effective target for biological treatment of liver cancer and is a potential biomarker for HCC diagnosis. Small molecular nucleotides targeting VASN are promising biological therapies to HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available